Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Safety Study of Galcanezumab in Episodic or Chronic Cluster Headache
2015-005234-21Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of galcanezumab in Cluster Headache (CH), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants With Treatment Emergent Adverse Events or Serious Adverse Events. Started Jun 2016; status: completed.
02
Drugs
galcanezumab
03
Conditions
Cluster Headache (CH)
Beyond the preview
Go deeper on 2015-005234-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005234-21.